Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

17.24USD
2:29am IST
Change (% chg)

$-0.37 (-2.10%)
Prev Close
$17.61
Open
$17.43
Day's High
$17.47
Day's Low
$17.00
Volume
1,772,058
Avg. Vol
2,051,341
52-wk High
$36.94
52-wk Low
$16.64

Latest Key Developments (Source: Significant Developments)

Mylan Says 2019 Revenue From Wixela To Be Slightly Lower Than Expected
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Mylan NV ::MYLAN NV CEO SAYS HAVE LAUNCHED NEW PRODUCTS WORTH $800 MILLION SO FAR THIS YEAR; ON TRACK TO BRING IN PRODUCTS WORTH $1 BILLION IN 2019 - CONF CALL.MYLAN EXECUTIVE SAYS ONGOING BUSINESS TRANSFORMATION PLAN INCLUDES RE-EVALUATING PIPELINE, EXPECTED TO HAVE A NEGATIVE IMPACT ON REVENUE - CONF CALL.MYLAN EXECUTIVE SAYS FULL-YEAR REVENUE FROM WIXELA TO BE SLIGHTLY LOWER THAN EXPECTED DUE TO CO'S "AGGRESSIVE SHARE RETENTION ACTIONS" - CONF CALL.MYLAN EXECUTIVE SAYS COMPLETED AROUND 80% TO 90% OF PRODUCT RE-EVALUATION IN THE U.S. AS PART OF BUSINESS TRANSFORMATION PLAN - CONF CALL.  Full Article

Mylan Initiates Voluntary Nationwide Recall Of One Lot Of Alprazolam Tablets Due To Potential Of Foreign Substance
Saturday, 26 Oct 2019 

Oct 25 (Reuters) - Mylan NV ::MYLAN PHARMACEUTICALS INITIATES VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF ALPRAZOLAM TABLETS, USP C-IV 0.5 MG, DUE TO THE POTENTIAL OF FOREIGN SUBSTANCE.MYLAN NV - LOT IS BEING RECALLED DUE TO POTENTIAL PRESENCE OF FOREIGN SUBSTANCE.MYLAN NV - CLINICAL IMPACT FROM FOREIGN MATERIAL, IF PRESENT, EXPECTED TO BE RARE, BUT REMOTE RISK OF INFECTION TO PATIENT CANNOT BE RULED OUT.  Full Article

Biocon And Mylan Launch First Insulin In Australia
Thursday, 3 Oct 2019 

Oct 3 (Reuters) - Biocon Ltd ::BIOCON AND MYLAN LAUNCH FIRST INSULIN GLARGINE BIOSIMILAR, SEMGLEE, IN AUSTRALIA.  Full Article

Mylan Finalizes Previously Disclosed Settlement With U.S. Securities And Exchange Commission
Friday, 27 Sep 2019 

Mylan NV ::MYLAN FINALIZES PREVIOUSLY DISCLOSED SETTLEMENT WITH U.S. SECURITIES AND EXCHANGE COMMISSION.MYLAN NV - SETTLEMENT FULLY RESOLVES SEC'S INVESTIGATION.  Full Article

U.S. SEC says Mylan to pay $30 million over EpiPen
Friday, 27 Sep 2019 

Sept 27 (Reuters) - u.s. Sec says mylan to pay $30 million for disclosure and accounting failures relating to epipen:.  Full Article

Revance Therapeutics Inc - Co & Mylan Ireland Amended Collaboration & License Agreement Dated Feb 28, 2018
Tuesday, 27 Aug 2019 

Aug 27 (Reuters) - Revance Therapeutics Inc ::REVANCE THERAPEUTICS INC - CO & MYLAN IRELAND AMENDED COLLABORATION & LICENSE AGREEMENT DATED FEB 28, 2018.REVANCE- WILL EXTEND TIME PERIOD FOR MYLAN TO DECIDE ON CONTINUATION OF DEVELOPMENT OF BIOSIMILAR TO BRANDED BIOLOGIC PRODUCT (ONABOTULINUMTOXINA).REVANCE THERAPEUTICS INC - MYLAN HAS AGREED TO PAY CO $5 MILLION INCREMENTAL TO PREVIOUSLY AGREED NON-REFUNDABLE UPFRONT PAYMENT OF $25 MILLION.  Full Article

Pfizer Says Upjohn Unit Has No Opioid Liabilities Which Will Transfer To New Company
Monday, 29 Jul 2019 

July 29 (Reuters) - Mylan NV ::PFIZER SAYS MANUFACTURING SUPPLY ISSUES CONTINUE TO AFFECT STERILE INJECTABLES BUSINESS; EXPECTS SIGNIFICANT IMPROVEMENT BY END OF 2019 - CONF. CALL.PFIZER SAYS TARGETING A U.S. REGULATORY SUBMISSION IN LATE Q4, 2019 OR EARLY 2020 FOR TANEZUMAB - CONF. CALL.PFIZER CEO SAYS CANNOT SUPPORT SENATE BILL ON DRUG PRICING AS IT IS WRITTEN ALTHOUGH THERE ARE SOME POSITIVES - CONF. CALL.PFIZER SAYS UPJOHN HAS NO OPIOID LIABILITIES WHICH WILL TRANSFER TO NEW COMPANY- CONF. CALL.  Full Article

Mylan Reports Q2 Loss Per Share $0.33
Monday, 29 Jul 2019 

July 29 (Reuters) - Mylan NV ::MYLAN REPORTS SECOND QUARTER 2019 RESULTS.Q2 GAAP LOSS PER SHARE $0.33.QTRLY TOTAL REVENUES OF $2.85 BILLION, UP 2% COMPARED TO PRIOR YEAR PERIOD.Q2 ADJUSTED EARNINGS PER SHARE $1.03.FOR FULL YEAR 2019, REAFFIRMING GUIDANCE RANGES FOR TOTAL REVENUE OF $11.5 BILLION TO $12.5 BILLION.QTRLY NORTH AMERICA SEGMENT NET SALES OF $1.02 BILLION, UP 2% ON AN ACTUAL AND CONSTANT CURRENCY BASIS.QTRLY EUROPE SEGMENT NET SALES OF $989.6 MILLION, FLAT, UP 6% ON A CONSTANT CURRENCY BASIS.Q2 EARNINGS PER SHARE VIEW $0.95, REVENUE VIEW $2.83 BILLION -- REFINITIV IBES DATA.REMAIN ON TRACK TO DELIVER ON 2019 GUIDANCE.FOR FY REAFFIRMING GUIDANCE RANGES ADJUSTED EPS, ADJUSTED FREE CASH FLOW RANGE.DURING SECOND QUARTER OF 2019, RECORDED A NET CHARGE OF $20.9 MILLION IN LITIGATION SETTLEMENTS AND OTHER CONTINGENCIES, NET.DURING THREE MONTHS ENDED JUNE 30, RECOGNIZED EXPENSE OF ABOUT $18.0 MILLION FOR SETTLEMENT IN PRINCIPLE RELATED TO MODAFINIL ANTITRUST MATTER.FY2019 EARNINGS PER SHARE VIEW $4.26, REVENUE VIEW $11.63 BILLION -- REFINITIV IBES DATA.  Full Article

Pfizer Nears Deal To Combine Off-Patent Drug Business With Mylan - WSJ
Saturday, 27 Jul 2019 

July 27 (Reuters) - :PFIZER NEARS DEAL TO COMBINE OFF-PATENT DRUG BUSINESS WITH MYLAN - WSJ.PFIZER & MYLAN DISCUSSED STOCK DEAL IN WHICH MYLAN SHAREHOLDERS WOULD OWN LITTLE MORE THAN 40% OF NEW ENTITY & PFIZER SHAREHOLDERS THE REMAINDER - WSJ.PFIZER WOULD RECEIVE ABOUT $12 BILLION IN PROCEEDS FROM A NEW SALE OF DEBT- WSJ.  Full Article

Theravance Biopharma and Mylan Expand YUPELRI Development and Commercialization Agreement to Include China and Adjacent Territories
Friday, 14 Jun 2019 

June 14 (Reuters) - Mylan NV ::THERAVANCE BIOPHARMA AND MYLAN EXPAND YUPELRI® (REVEFENACIN) DEVELOPMENT AND COMMERCIALIZATION AGREEMENT TO INCLUDE CHINA AND ADJACENT TERRITORIES.MYLAN NV - EXPANSION OF DEVELOPMENT & COMMERCIALIZATION DEAL FOR NEBULIZED REVEFENACIN TO INCLUDE CHINA & SOME ADJACENT TERRITORIES.MYLAN NV - THERAVANCE BIOPHARMA WILL RECEIVE AN UPFRONT PAYMENT OF $18.5 MILLION UNDER TERMS.MYLAN NV - MYLAN WILL BE RESPONSIBLE FOR ALL ASPECTS OF DEVELOPMENT AND COMMERCIALIZATION IN PARTNERED REGIONS.MYLAN NV - THERAVANCE BIOPHARMA ALSO TO BE ELIGIBLE TO RECEIVE ADDITIONAL POTENTIAL DEVELOPMENT AND SALES MILESTONES TOTALING $54 MILLION.  Full Article

UPDATE 3-Mylan shares slide after warning of hit to revenue

Nov 5 Generic drugmaker Mylan NV said on Tuesday reevaluation of its portfolio of medicines will continue next year and cautioned of a hit to revenue, and its shares nearly 6%.